Drug Manufacturers - General Industry: Stock Analysis & Valuation
Industry: Drug Manufacturers - General | Sector: Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
The Drug Manufacturers - General industry represents a focused group of companies with highly similar business models, competitive dynamics, and market forces. This granular view makes it easier to spot which companies have sustainable competitive advantages and which are likely overvalued or undervalued.
Your Industry Knowledge = Investment Edge
If you work in Drug Manufacturers - General, follow industry news, or understand the competitive landscape, you have a significant advantage over Wall Street analysts. Use this knowledge to evaluate which companies have durable moats, realistic growth prospects, and strong margins of safety.
Drug Manufacturers - General Stocks: Value Metrics
Review the stocks in this list to compare valuations, cash flow metrics, and value investing indicators. Look for companies trading below intrinsic value with sustainable competitive advantages.
| Company | Current Price | Current Price Discount 10 years |
|---|---|---|
| Enanta Pharmaceuticals (ENTA) |
$7.62 | unknown |
| Theravance Biopharma (TBPH) |
$17.03 | none |
| Atossa Therapeutics (ATOS) |
$1.59 | none |
| Elanco Animal Health Incorporated (ELAN) |
$25.74 | none |
| Rafael Holdings (RFL) |
$0.92 | none |
| KalVista Pharmaceuticals (KALV) |
$27.00 | none |
| Arrowhead Pharmaceuticals (ARWR) |
$41.37 | none |
| Cumberland Pharmaceuticals (CPIX) |
$5.84 | none |
| Edge Therapeutics (EDGE) |
$46.01 | none |
| Alnylam Pharmaceuticals (ALNY) |
$143.82 | unknown |
| Intra-Cellular Therapies (ITCI) |
$0.00 | none |
| Ultragenyx Pharmaceutical (RARE) |
$17.22 | none |
| Teva Pharmaceutical Industries Limited (TEVA) |
$38.54 | 11.0% |
| Xencor (XNCR) |
$34.01 | none |
| Tonix Pharmaceuticals Holding Corp. (TNXP) |
$2.55 | none |
| Supernus Pharmaceuticals (SUPN) |
$28.35 | none |
| Rocket Pharmaceuticals (RCKT) |
$1.95 | none |
| Vanda Pharmaceuticals (VNDA) |
$3.67 | unknown |
| Corcept Therapeutics Incorporated (CORT) |
$64.98 | none |
| Omeros Corporation (OMER) |
$13.21 | none |
| Corbus Pharmaceuticals Holdings (CRBP) |
$2.06 | none |
| Savara (SVRA) |
$4.26 | none |
| Phibro Animal Health Corporation (PAHC) |
$33.29 | none |
| Heron Therapeutics (HRTX) |
$0.25 | none |
| TherapeuticsMD (TXMD) |
$1.71 | none |
| Bristol-Myers Squibb Company (BMY) |
$58.80 | none |
| Catalyst Pharmaceuticals (CPRX) |
$0.00 | none |
| TG Therapeutics (TGTX) |
$63.34 | none |
| Verrica Pharmaceuticals (VRCA) |
$2.74 | none |
| Abeona Therapeutics (ABEO) |
$2.42 | none |
| Ironwood Pharmaceuticals (IRWD) |
$4.70 | unknown |
| Veru (VERU) |
$1.94 | none |
| Johnson & Johnson (JNJ) |
$270.47 | none |
| Perrigo Company plc (PRGO) |
$15.94 | 88.9% |
| China Pharma Holdings (CPHI) |
$0.44 | unknown |
| Alkermes plc (ALKS) |
$44.94 | none |
| Ocular Therapeutix (OCUL) |
$5.57 | none |
| SIGA Technologies (SIGA) |
$2.40 | 80.4% |
| Axsome Therapeutics (AXSM) |
$129.36 | none |
| Selecta Biosciences (SELB) |
$0.00 | none |
| Ocuphire Pharma (OCUP) |
$0.00 | none |
| LifeVantage Corporation (LFVN) |
$4.15 | none |
| Regeneron Pharmaceuticals (REGN) |
$920.69 | none |
| Ionis Pharmaceuticals (IONS) |
$26.58 | none |
| Cara Therapeutics (CARA) |
$0.00 | none |
| Jaguar Health (JAGX) |
$0.23 | none |
| Inovio Pharmaceuticals (INO) |
$1.76 | none |
| Collegium Pharmaceutical (COLL) |
$24.72 | none |
| Aurinia Pharmaceuticals (AUPH) |
$14.70 | none |
| Agios Pharmaceuticals (AGIO) |
$27.60 | none |
| Viatris (VTRS) |
$19.63 | none |
| SCYNEXIS (SCYX) |
$2.38 | none |
| PTC Therapeutics (PTCT) |
$56.42 | none |
| Zoetis (ZTS) |
$79.11 | none |
| India Globalization Capital (IGC) |
$0.17 | none |
| Sarepta Therapeutics (SRPT) |
$13.33 | none |
| Innoviva (INVA) |
$18.41 | none |
| Amicus Therapeutics (FOLD) |
$0.00 | unknown |
| Evolus (EOLS) |
$6.52 | none |
| Wave Life Sciences Ltd. (WVE) |
$2.56 | none |
| Prestige Consumer Healthcare (PBH) |
$49.63 | 22.5% |
| Jazz Pharmaceuticals plc (JAZZ) |
$230.26 | 26.9% |
| Geron Corporation (GERN) |
$0.87 | unknown |
| Galectin Therapeutics (GALT) |
$2.69 | none |
| Viking Therapeutics (VKTX) |
$24.77 | none |
| Puma Biotechnology (PBYI) |
$7.05 | none |
| Amphastar Pharmaceuticals (AMPH) |
$28.25 | none |
| Catalyst Biosciences (CBIO) |
$13.00 | none |
| Esperion Therapeutics (ESPR) |
$0.00 | none |
| United Therapeutics Corporation (UTHR) |
$554.73 | none |
| BioMarin Pharmaceutical (BMRN) |
$60.41 | none |
| AcelRx Pharmaceuticals (ACRX) |
$0.00 | none |
| BeiGene, Ltd. (BGNE) |
$0.00 | none |
| Nektar Therapeutics (NKTR) |
$30.20 | unknown |
| XBiotech (XBIT) |
$1.73 | none |
| Pfizer (PFE) |
$27.40 | 56.7% |
| Prothena Corporation plc (PRTA) |
$8.22 | none |
| Immunic (IMUX) |
$6.99 | none |
| AnaptysBio (ANAB) |
$46.63 | none |
| Assertio Holdings (ASRT) |
$23.50 | none |
| Abbott Laboratories (ABT) |
$103.00 | none |
| Catalent (CTLT) |
$0.00 | unknown |
| ARCA biopharma (ABIO) |
$0.00 | none |
| Oncolytics Biotech (ONCY) |
$0.35 | none |
| FibroGen (FGEN) |
$0.00 | none |
| Lexicon Pharmaceuticals (LXRX) |
$1.53 | unknown |
| Aptevo Therapeutics (APVO) |
$0.40 | none |
| Akebia Therapeutics (AKBA) |
$0.39 | none |
| Zai Lab Limited (ZLAB) |
$21.03 | none |
| Northwest Biotherapeutics (NWBO) |
$0.13 | none |
| Elite Pharmaceuticals (ELTP) |
$0.32 | none |
| ANI Pharmaceuticals (ANIP) |
$68.55 | none |
| NanoViricides (NNVC) |
$1.14 | none |
| Pacira BioSciences (PCRX) |
$36.48 | unknown |
| OPKO Health (OPK) |
$1.57 | unknown |
| Rigel Pharmaceuticals (RIGL) |
$40.09 | unknown |
Industry-Level Investment Strategy
Industry analysis allows you to compare companies operating in nearly identical markets. This granularity reveals which businesses have true competitive advantages versus those merely benefiting from industry tailwinds.
Industry Leaders
Established companies with:
- Strong brand recognition
- Pricing power
- Economies of scale
- Distribution advantages
- Customer loyalty
Often safer, but may trade at premium valuations
Niche Players
Specialists focusing on:
- Specific market segments
- Unique technologies
- Geographic advantages
- Specialized expertise
- Customer relationships
Can offer excellent value if moat is strong
Emerging Competitors
Growth companies with:
- Innovative business models
- Technology advantages
- Market share gains
- Scalable platforms
- Strong growth rates
Higher risk but potential for outsized returns
Key Questions for Drug Manufacturers - General Stocks
Competitive Analysis:
- What creates customer switching costs?
- How sustainable is the competitive moat?
- Can new entrants easily disrupt the market?
- What drives profitability differences?